Lori A. Kunkel M.D.*
Lori A. Kunkel, M.D., has served on the Board since November 2016 and currently serves on the Board of Directors at Nurix Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and K36 Therapeutics, Inc. Previously, she served on the Board of Directors of Loxo Oncology, Amphivena, Harpoon Therapeutics, Tocagen, Inc., and Maverick Therapeutics, Inc. Dr. Kunkel is a clinical advisor to Atreca, Inc., Elevation Oncology, Enliven Therapeutics, Indapta Therapeutics, Jasper Therapeutics, Oryzon Genomics, S.A., Pyramid Biosciences, and Rain Therapeutics, Inc. Previously, she served as Chief Medical Officer at Loxo Oncology, Pharmacyclics, ACT, Syndax, and Proteolix (acquired by Onyx), as well as in senior clinical roles at Baxter Healthcare, Chiron, and Genentech, Inc. Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at the University of California, Los Angeles. She trained in internal medicine at Baylor College of Medicine, hematology at the University of Southern California and oncology at the University of California, Los Angeles, earning board certifications in these specialties. Dr. Kunkel received a B.A. from the University of California, San Diego and an M.D. from the University of Southern California.
Nominating and Governance